SCHEMBL665209

SCHEMBL665209

CNc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC

nearest known ligand 0.74

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.74
KMT2A Q03164 1/20 0.74
ADORA3 P0DMS8 2/20 0.66
ADORA1 P30542 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29421079 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL18503544 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL20449961 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL25098313 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL7197194 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL25097801 1.00 MEN1 (0.74) MEN1KMT2AADORA3ADORA1
SCHEMBL26501998 0.92 MEN1 (0.63) MEN1KMT2AADORA3ADORA1
SCHEMBL9413275 0.91 MEN1 (0.62) MEN1KMT2AADORA3ADORA1
SCHEMBL7922093 0.91 MEN1 (0.73) MEN1KMT2AADORA3ADORA1
SCHEMBL9413276 0.90 MEN1 (0.72) MEN1KMT2AADORA3ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1593 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034204-A1 RNA ENCODING VIRUS-LIKE PARTICLES AND USES THEREOF SEQIRUS INC (US) 2026-02-05 US claimed
EP-4634380-A1 INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION ModernaTX, Inc. (US) 2025-10-22 EP claimed
WO-2025137275-A1 NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME MODERNATX, INC. (US) 2025-06-26 WO claimed
WO-2025124917-A1 SMALL NON-CODING RNA NANOPORE SEQUENCING HUMMINGBIRD DIAGNOSTICS GMBH (DE) 2025-06-19 WO claimed
EP-4568697-A1 RNA ENCODING VIRUS-LIKE PARTICLES AND USES THEREOF Seqirus Inc. (US) 2025-06-18 EP claimed
EP-4565692-A2 INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION ModernaTX, Inc. (US) 2025-06-11 EP claimed
EP-4561537-A2 LIPID NANOPARTICLES FOR IMMUNOTHERAPY TRUSTEES OF TUFTS COLLEGE (US) 2025-06-04 EP claimed
WO-2025111430-A1 CHEMICAL MODIFICATIONS IN mRNA POLY(A) TAIL PRIME MEDICINE, INC. (US) 2025-05-30 WO claimed
US-20250101507-A1 Methods of Analyzing Capped Ribonucleic Acids THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-03-27 US claimed
WO-2025034727-A1 TRANSLATIONAL MODULATING ELEMENTS FOR MRNA MOLECULES CAPPED WITH 5'-CAP ANALOGS, MRNA MOLECULES INCLUDING THE SAME, AND METHODS USING THE SAME YALE UNIVERSITY (US) 2025-02-13 WO claimed
US-20210348224-A1 Methods of Analyzing Capped Ribonucleic Acids THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-11-11 US claimed
US-20190175690-A1 COMPOSITIONS AND METHODS FOR CARDIAC REPAIR CHILDREN'S MEDICAL CENTER CORPORATION (US) 2019-06-13 US claimed
EP-3460064-A1 EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) The General Hospital Corporation d/b/a Massachusetts General Hospital (US) 2019-03-27 EP claimed
US-10086043-B2 Efficient protein expression in vivo using modified RNA (MOD-RNA) THE GENERAL HOSPITAL CORPORATION (US) 2018-10-02 US claimed
EP-2694660-B1 EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) MASSACHUSETTS GEN HOSPITAL (US) 2018-08-08 EP claimed
US-9719084-B2 Co-transcriptional assembly of modified RNA nanoparticles THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2017-08-01 US claimed
US-20150203842-A1 CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES 2015-07-23 US claimed
US-20140073687-A1 EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) IMMUNE DISEASE INSTITUTE, INC. (US) 2014-03-13 US claimed
WO-2014039809-A2 CO-TRANSCRIPTIONAL ASSEMBLY OF MODIFIED RNA NANOPARTICLES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2014-03-13 WO claimed
US-20030007961-A1 Orthomolecular vitamin E derivatives WILBURN MICHAEL D (US) 2003-01-09 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190175690-A1 COMPOSITIONS AND METHODS FOR CARDIAC REPAIR YAP1, TNNI3, FABP3 MEN1 4403/4885KMT2A 1996/4885ADORA3 4202/4885
US-20030007961-A1 Orthomolecular vitamin E derivatives RBP4, RBP1, VDR MEN1 3493/4885KMT2A 4864/4885ADORA3 1274/4885
US-20260034204-A1 RNA ENCODING VIRUS-LIKE PARTICLES AND USES THEREOF HNRNPA1, UPF1, PRNP MEN1 2764/4885KMT2A 1929/4885ADORA3 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.